What interviewers actually evaluate

Regeneron Pharmaceuticals marketing interviews test whether candidates understand how to develop and execute pharmaceutical marketing programs within FDA promotional regulations – where direct-to-consumer advertising for biologic medicines requires fair balance between efficacy claims and risk information, where healthcare provider marketing must stay within the boundaries of approved labeling and the medical affairs firewall, and where DUPIXENT's established market position in atopic dermatitis and its expansion across multiple Type 2 inflammatory conditions creates a multi-indication brand management challenge distinct from single-indication pharmaceutical brands. Marketing at Regeneron spans DUPIXENT branded and disease awareness marketing (where DTC advertising for DUPIXENT in atopic dermatitis, asthma, and other approved indications must present efficacy claims with balanced presentation of the safety information in the approved prescribing information – requirements that FDA's Office of Prescription Drug Promotion enforces, and that distinguish pharmaceutical DTC from standard consumer advertising where risk disclosure is optional – and where unbranded disease awareness campaigns that educate patients about moderate-to-severe atopic dermatitis as an inflammatory condition rather than a simple skin problem reach undiagnosed patients who may not have sought specialist care before the campaign), healthcare provider marketing and professional education (where detail visits, speaker programs, peer-to-peer education, and journal advertising must communicate DUPIXENT and EYLEA clinical data accurately within label and where the medical education content that medical affairs can present differs from the promotional content that commercial representatives can discuss – with the fair balance and substantiation requirements of pharmaceutical promotion applying to all commercial communications including digital channels), payer marketing and formulary access programs (where gaining broad formulary access for high-cost biologics requires communicating clinical differentiation and health economic value to medical directors and pharmacy and therapeutics committees in terms that justify formulary placement decisions and minimize restrictive prior authorization criteria that create access barriers for appropriate patients), and co-promotion marketing coordination with Sanofi (where DUPIXENT and LIBTAYO DTC campaigns, professional marketing programs, and medical education initiatives require alignment between Regeneron and Sanofi commercial organizations that share co-promotion responsibilities with each company contributing field force and marketing investment according to the collaboration agreement). Interviewers evaluate whether candidates understand FDA-regulated pharmaceutical DTC advertising, healthcare provider promotional compliance, payer value communication, and co-promotion marketing coordination for shared biologics.

Start your free Regeneron Pharmaceuticals Marketing practice session.

What interviewers actually evaluate

Pharmaceutical DTC Compliance, HCP Professional Education, and Payer Access Marketing

Regeneron marketing interviews probe whether candidates understand how pharmaceutical marketing differs from consumer brand marketing in the FDA promotional regulation constraint (pharmaceutical companies that make efficacy claims for prescription drugs in advertising must present the drug's most important risks with prominence and readability comparable to the efficacy information – the fair balance requirement that turns every DUPIXENT television commercial into a structured presentation that names injection site reactions, eye problems, and other significant adverse events alongside the efficacy claim, and that can result in FDA warning letters and required corrective advertising when violated), the medical affairs boundary (pharmaceutical marketing departments can promote within approved labeling but cannot discuss unapproved uses, ongoing clinical investigations, or comparative efficacy claims that go beyond what the label supports – medical affairs communicates to scientific audiences about broader clinical context including investigational data, and the promotional-medical boundary must be carefully maintained in every physician interaction where medical information requests that should go to medical affairs are not handled by commercial field representatives), and the co-promotion alignment complexity (DUPIXENT's co-promotion with Sanofi requires that both companies' marketing materials communicate consistent messages about the product – a Regeneron-developed DUPIXENT advertisement must be reviewed and approved by both companies' regulatory review processes before deployment, and strategic marketing decisions about indication focus, messaging hierarchy, and campaign creative direction require joint alignment through the collaboration's governance committee structure that can slow the decision timeline compared to wholly-owned brand management).

The patient identification challenge is a core marketing strategy dimension for DUPIXENT: the undiagnosed and under-diagnosed population of moderate-to-severe atopic dermatitis patients who are not currently under specialist care represents the largest single growth opportunity for DUPIXENT, and the disease awareness campaigns and patient education programs that reach these patients before they visit a dermatologist or allergist are among the most valuable marketing investments Regeneron makes – requiring marketers who understand how to design campaigns that help patients recognize their disease severity and seek specialist evaluation without the campaign itself crossing into branded promotion before the diagnosis and treatment decision is made.

What gets scored in every session

Specific, sentence-level feedback.

Dimension	What it measures	How to answer
FDA-compliant pharmaceutical DTC advertising	Do you understand the fair balance, accurate claims, and substantiation requirements that apply to DUPIXENT DTC advertising – how risk information must be presented in broadcast, print, and digital channels, what claim types require clinical trial data support, and how the FDA's Office of Prescription Drug Promotion enforces promotional standards? We flag marketing answers that describe pharmaceutical DTC as equivalent to consumer advertising with added risk disclosure rather than a distinct regulatory compliance context.	Fair balance presentation requirements, claim substantiation standards, OPDP enforcement process
Disease awareness and unbranded patient marketing	Can you describe how to design unbranded disease awareness campaigns that help patients identify themselves as moderate-to-severe atopic dermatitis patients appropriate for specialist evaluation – what the regulatory distinction between unbranded disease awareness and branded promotion is, how to drive dermatologist and allergist visits without crossing into branded promotion, and how to measure whether disease awareness investment converts to DUPIXENT-appropriate patient identification? We score whether your disease awareness strategy engages with the regulatory and conversion measurement challenges.	Unbranded vs branded regulatory distinction, specialist referral conversion tracking, appropriate patient identification measurement
HCP professional marketing and promotional compliance	Do you understand how to market DUPIXENT and EYLEA to healthcare providers within the requirements of pharmaceutical promotional compliance – what activities require regulatory review and approval, what peer-to-peer education programs are permissible, and how to maintain the boundary between commercial promotion and medical affairs scientific communication? We detect marketing answers that treat HCP promotion as open-ended scientific communication without engaging with FDA promotional regulations.	Promotional materials review process, speaker program compliance, medical-commercial boundary maintenance
Payer marketing and health economic value communication	Can you describe how to develop payer marketing for a high-cost biologic – what the components of a payer value story for DUPIXENT include, how health economics and outcomes research data supports formulary access discussions, and how to communicate differentiated value to payers who are considering biosimilar substitution policies that would affect EYLEA formulary position? We flag marketing answers that treat payer access as a sales function rather than a marketing strategy component.	Value dossier marketing utilization, cost-effectiveness communication, formulary position defense

How a session works

Step 1: Choose a Regeneron Pharmaceuticals marketing scenario – DUPIXENT DTC advertising development and FDA compliance, unbranded disease awareness marketing for undiagnosed moderate-to-severe atopic dermatitis patients, healthcare provider professional marketing and promotional compliance, or payer marketing and health economic value communication.

Step 2: The AI interviewer asks realistic Regeneron-style questions: how you would evaluate a proposed DUPIXENT television commercial concept where the voiceover presents DUPIXENT's efficacy claims in the first 45 seconds and the risk disclosure runs in the final 15 seconds in smaller text while images continue showing the patient character enjoying normal activities – identifying what FDA compliance concerns the execution raises and how you would revise the brief to ensure fair balance compliance before submitting for regulatory review, how you would design a 12-month disease awareness campaign for moderate-to-severe atopic dermatitis that reaches adult patients who have been managing their disease with over-the-counter products and primary care visits without ever seeing a dermatologist – including channel selection, patient identification message, and the measurement framework that connects disease awareness campaign reach to actual dermatology visits and DUPIXENT prescriptions, or how you would develop the payer marketing strategy for DUPIXENT in the commercial health plan segment where three competing biologics and JAK inhibitors are available and where payers are under cost pressure from employers to manage specialty drug spending on the atopic dermatitis category.

Step 3: You respond as you would in the actual interview. The system scores your answer on FDA DTC compliance, disease awareness strategy, HCP professional marketing compliance, and payer value communication.

Step 4: You get sentence-level feedback on what demonstrated genuine pharmaceutical marketing expertise and what needs stronger FDA regulatory compliance understanding or payer access strategy specificity.

Frequently Asked Questions

What are the FDA requirements for fair balance in pharmaceutical DTC advertising?
The FDA requires that pharmaceutical DTC advertising that makes efficacy claims present the drug's most important risks – those listed in the boxed warning and other significant risks from the prescribing information – with a reasonable balance between the prominence given to efficacy information and the prominence given to risk information. In broadcast advertising (television, radio), this risk information must be presented in the major statement – an audible disclosure of the drug's major risks during the advertisement – while the brief summary in print can reference the approved prescribing information. Digital advertising creates new fair balance challenges: banner ads and social media posts with limited space cannot contain full risk disclosure, and FDA's guidance on digital promotion clarifies that some digital formats require risk disclosure immediately adjacent to any efficacy claim while others may use a layered disclosure approach with a hyperlink to fuller risk information. Regeneron's regulatory review process requires that all promotional materials including digital content pass through medical, legal, and regulatory review before deployment to ensure fair balance compliance.

How does disease awareness marketing differ from branded pharmaceutical promotion?
Disease awareness campaigns that educate patients about a medical condition – atopic dermatitis as a chronic inflammatory disease, not just a skin irritation – without naming a specific product are not subject to the same FDA promotional requirements as branded advertising. These campaigns can describe disease signs, symptoms, and severity criteria, encourage patients to seek medical evaluation, and promote patient-physician discussion without constituting product promotion. The regulatory distinction becomes important because disease awareness campaigns can reach the large population of undiagnosed or under-treated moderate-to-severe AD patients before they are in the specialist care pathway where DUPIXENT prescriptions originate. When disease awareness campaigns are created by or coordinated with companies whose products treat the condition, FDA scrutiny increases – companies must ensure that unbranded campaigns are genuinely independent of branded promotion strategy and are not functioning as thinly disguised product marketing campaigns that create awareness of the product rather than the disease.

How do HCP speaker programs work within pharmaceutical promotional compliance requirements?
Healthcare provider speaker programs engage physicians who are paid to present clinical data about a pharmaceutical product to their peers at dinner meetings, hospital grand rounds, or professional conferences. Speaker programs are promotional activities subject to FDA promotional regulations – speakers must present only information consistent with the approved labeling, must follow the approved slide deck and not deviate to discuss unapproved indications, and must disclose their financial relationship with the pharmaceutical company to the audience. PhRMA's voluntary code on interactions with healthcare professionals and OIG compliance guidance establish industry standards for speaker program design and execution, including that speaker selection should be based on scientific expertise rather than prescribing volume and that speaker fees should reflect fair market value for the speaker's time. Regeneron's compliance program specifies the procedures for speaker program management, including speaker training, slide approval, event documentation, and aggregate spend reporting under the Sunshine Act.

How does payer marketing work for high-cost biologics like DUPIXENT?
Payer marketing for DUPIXENT involves engaging with the medical directors, pharmacy and therapeutics committee members, and health outcomes analysts at health plans and pharmacy benefit managers who make formulary placement and coverage policy decisions. These audiences evaluate new biologic therapies on clinical evidence quality, the strength of the patient population indication, cost-effectiveness relative to existing treatment options, and the rebate economics that the pharmaceutical company offers in exchange for favorable formulary placement. Regeneron's payer marketing strategy positions DUPIXENT's clinical differentiation for moderate-to-severe patients – its demonstrated long-term efficacy in reducing disease burden, the real-world healthcare utilization reductions in DUPIXENT-treated patients, and its approvals in conditions like atopic dermatitis where no prior biologics were approved – as justification for broad formulary access with limited prior authorization restrictions rather than the step therapy and PA barriers that increase payer control over utilization but create access friction for appropriate patients.

How does Sanofi co-promotion affect marketing decision-making?
DUPIXENT's co-promotion with Sanofi requires that major marketing decisions including DTC campaign development, payer marketing strategy, and professional promotion priorities be aligned between Regeneron and Sanofi commercial teams through the joint commercialization committee governance structure. Both companies' regulatory review processes must approve promotional materials before deployment, which extends the development timeline compared to single-company brands. Strategic decisions about indication emphasis – how to balance marketing investment between established indications like atopic dermatitis and newly approved indications like food allergies – require joint alignment because each company's portfolio strategy may weight the indications differently based on their respective competitive positions and commercial infrastructure. Regeneron marketers who work on DUPIXENT develop expertise in navigating the joint governance process and building the cross-company relationships that enable faster alignment on tactical decisions that the formal committee structure would slow if it were invoked for every marketing execution decision.